Total Payments
$5,697
2022 Payments
$101.67
Companies
40
Transactions
355
Medicare Patients
3,586
Medicare Billing
$957,563
Payment Breakdown by Category
Food & Beverage$5,628 (98.8%)
Education$68.69 (1.2%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,628 | 348 | 98.8% |
| Education | $68.69 | 7 | 1.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $675.47 | 42 | $0 (2021) |
| Genentech USA, Inc. | $552.27 | 34 | $0 (2018) |
| Janssen Biotech, Inc. | $538.26 | 32 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $427.21 | 32 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $326.58 | 23 | $0 (2018) |
| PFIZER INC. | $308.47 | 29 | $0 (2021) |
| Celgene Corporation | $291.80 | 18 | $0 (2018) |
| Amgen Inc. | $259.15 | 17 | $0 (2021) |
| GENZYME CORPORATION | $231.30 | 10 | $0 (2021) |
| Merck Sharp & Dohme Corporation | $211.26 | 16 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $101.67 | 1 | Sobi, Inc ($101.67) |
| 2021 | $313.91 | 12 | GENZYME CORPORATION ($114.80) |
| 2020 | $16.26 | 1 | GENZYME CORPORATION ($16.26) |
| 2019 | $128.19 | 4 | Janssen Biotech, Inc. ($100.71) |
| 2018 | $2,758 | 177 | Novartis Pharmaceuticals Corporation ($412.39) |
| 2017 | $2,379 | 160 | Genentech USA, Inc. ($332.12) |
All Payment Transactions
355 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/26/2022 | Sobi, Inc | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $101.67 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/26/2021 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $22.34 | General |
| Category: Oncology | ||||||
| 09/28/2021 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $20.81 | General |
| Category: Oncology | ||||||
| 09/14/2021 | GENZYME CORPORATION | ELITEK (Biological) | Food and Beverage | In-kind items and services | $92.71 | General |
| Category: Oncology | ||||||
| 08/04/2021 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $17.40 | General |
| Category: Oncology | ||||||
| 07/27/2021 | Novartis Pharmaceuticals Corporation | KISQALI (Drug), FEMARA, PIQRAY | Food and Beverage | In-kind items and services | $21.12 | General |
| Category: ONCOLOGY | ||||||
| 07/20/2021 | Amgen Inc. | Kyprolis (Drug) | Food and Beverage | In-kind items and services | $20.31 | General |
| Category: Oncology | ||||||
| 07/13/2021 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug), COSELA | Food and Beverage | In-kind items and services | $26.08 | General |
| Category: ONCOLOGY | ||||||
| 06/11/2021 | PFIZER INC. | BRAFTOVI (Drug), MEKTOVI | Education | In-kind items and services | $13.04 | General |
| Category: ONCOLOGY | ||||||
| 06/08/2021 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $23.47 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 05/18/2021 | Novartis Pharmaceuticals Corporation | KISQALI (Drug), FEMARA, PIQRAY | Food and Beverage | In-kind items and services | $22.62 | General |
| Category: ONCOLOGY | ||||||
| 04/27/2021 | GENZYME CORPORATION | SARCLISA (Biological), ELITEK | Food and Beverage | In-kind items and services | $22.09 | General |
| Category: Oncology | ||||||
| 11/02/2020 | GENZYME CORPORATION | ELITEK (Biological), SARCLISA | Food and Beverage | In-kind items and services | $16.26 | General |
| Category: Oncology | ||||||
| 11/11/2019 | GENZYME CORPORATION | ELITEK (Drug), TUMOR LYSIS SYNDROME - DISEASE | Food and Beverage | In-kind items and services | $12.68 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2019 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $2.44 | General |
| Category: Oncology | ||||||
| 03/14/2019 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $98.27 | General |
| Category: Oncology | ||||||
| 02/11/2019 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $14.80 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 12/18/2018 | Bayer HealthCare Pharmaceuticals Inc. | Xofigo (Drug) | Food and Beverage | In-kind items and services | $13.18 | General |
| Category: Oncology | ||||||
| 12/17/2018 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA | Food and Beverage | In-kind items and services | $15.56 | General |
| Category: Oncology | ||||||
| 12/13/2018 | Amgen Inc. | Kyprolis (Biological), XGEVA | Food and Beverage | In-kind items and services | $14.66 | General |
| Category: Oncology | ||||||
| 12/12/2018 | E.R. Squibb & Sons, L.L.C. | EMPLICITI (Biological) | Food and Beverage | Cash or cash equivalent | $14.91 | General |
| Category: Oncology | ||||||
| 12/06/2018 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Food and Beverage | In-kind items and services | $24.08 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2018 | Genentech USA, Inc. | GAZYVA (Biological), Rituxan Hycela | Food and Beverage | In-kind items and services | $16.79 | General |
| Category: BioOncology | ||||||
| 12/03/2018 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $25.76 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 416 | 673 | $234,456 | $52,676 |
| 2022 | 5 | 514 | 756 | $147,016 | $68,937 |
| 2021 | 27 | 1,295 | 91,425 | $1.4M | $437,399 |
| 2020 | 29 | 1,361 | 81,099 | $1.4M | $398,552 |
Total Patients
3,586
Total Services
173,953
Medicare Billing
$957,563
Procedure Codes
71
All Medicare Procedures & Services
71 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 99 | 210 | $89,250 | $21,776 | 24.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 190 | 336 | $97,776 | $21,606 | 22.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 35 | 35 | $21,490 | $4,455 | 20.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 49 | 49 | $23,716 | $4,165 | 17.6% |
| 98968 | Telephone medical discussion provided by nonphysician professional, 21-30 minutes | Office | 2023 | 18 | 18 | $1,674 | $463.14 | 27.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 25 | 25 | $550.00 | $210.00 | 38.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 107 | 207 | $44,006 | $23,284 | 52.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 177 | 277 | $41,352 | $20,673 | 50.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 51 | 83 | $21,580 | $8,532 | 39.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 38 | 38 | $9,520 | $5,427 | 57.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 62 | 72 | $13,104 | $4,499 | 34.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 31 | 31 | $7,556 | $3,278 | 43.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 12 | 12 | $4,716 | $1,757 | 37.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 16 | 16 | $4,832 | $1,427 | 29.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 20 | 20 | $350.00 | $59.46 | 17.0% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 31 | 9,780 | $381,420 | $160,597 | 42.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 364 | 770 | $179,410 | $69,242 | 38.6% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2021 | 40 | 66,750 | $200,250 | $60,578 | 30.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 141 | 307 | $95,784 | $42,197 | 44.1% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 44 | 303 | $129,987 | $32,898 | 25.3% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2021 | 16 | 148 | $168,720 | $21,092 | 12.5% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 61 | 61 | $28,487 | $10,148 | 35.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2021 | 65 | 169 | $30,082 | $9,100 | 30.3% |
| 96367 | Infusion into a vein for therapy prevention or diagnosis additional sequential infusion up to 1 hour | Office | 2021 | 26 | 215 | $19,350 | $5,225 | 27.0% |
| 96375 | Injection of different drug or substance into a vein for therapy, diagnosis, or prevention | Office | 2021 | 48 | 358 | $22,196 | $4,560 | 20.5% |
About Dr. Thomas Grote, MD
Dr. Thomas Grote, MD is a Medical Oncology healthcare provider based in N Wilkesboro, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1215907993.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Grote, MD has received a total of $5,697 in payments from pharmaceutical and medical device companies, with $101.67 received in 2022. These payments were reported across 355 transactions from 40 companies. The most common payment nature is "Food and Beverage" ($5,628).
As a Medicare-enrolled provider, Grote has provided services to 3,586 Medicare beneficiaries, totaling 173,953 services with total Medicare billing of $957,563. Data is available for 4 years (2020–2023), covering 71 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location N Wilkesboro, NC
- Active Since 01/25/2006
- Last Updated 04/25/2022
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1215907993
Products in Payments
- IMBRUVICA (Drug) $419.93
- OPDIVO (Biological) $300.50
- Revlimid (Drug) $229.40
- JADENU (Drug) $212.10
- KEYTRUDA (Biological) $185.22
- KISQALI (Drug) $150.00
- NINLARO (Drug) $131.59
- GILOTRIF (Drug) $118.44
- GAZYVA (Biological) $117.20
- TAGRISSO (Drug) $116.92
- SUTENT (Drug) $112.17
- ELITEK (Biological) $108.97
- TECENTRIQ (Biological) $108.05
- DOPTELET (Drug) $101.67
- Avastin (Biological) $101.16
- Yescarta (Drug) $101.06
- JAKAFI (Drug) $100.63
- EMPLICITI (Biological) $99.54
- TASIGNA (Drug) $98.05
- LYNPARZA (Drug) $94.08
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.